[Medii] Starts disease awareness project for attending physicians on inherited retinal dystrophy (IRD)
*View in browser* *Medii*
Press release: May 14, 2024
**
Launch of disease awareness project for attending physicians regarding inherited retinal dystrophy (IRD)
*E-consulting improves IRD diagnosis rate and promotes appropriate treatment*
Medii Co., Ltd. (Shinjuku-ku, Tokyo, Representative Director: Hiroki Yamada, pronunciation: Medii) is conducting a disease awareness project for attending physicians with the aim of improving the diagnosis rate and optimizing treatment of hereditary retinal dystrophy. start.
*What is hereditary retinal dystrophy (IRD)*
IRD is a general term for inherited and progressive eye diseases in which retinal function is impaired due to genetic mutations. The most common diseases, such as retinitis pigmentosa and Leber’s congenital amaurosis, cause visual acuity to deteriorate as the disease progresses, and can even lead to blindness.
Until now, no fundamental treatment for IRD has been established, but recently, one of the causative genes of IRD, *RPE*
Research and development has made it possible to select innovative new drugs, such as a gene therapy drug that compensates for functional defects in 65 genes that was approved for the first time in Japan for an ophthalmological disease.
* History of the initiative *
IRD is a disease that requires a high level of specialized knowledge, and there are only a limited number of doctors in Japan who are familiar with IRD. Therefore, even if a revolutionary new drug appears, it is extremely difficult to accurately understand its effectiveness and safety and to prescribe it correctly according to the patient’s condition. Therefore, Medii has created a system that allows all doctors to easily access expert specialists with advanced knowledge in each field, with the aim of early detection and treatment optimization of rare and incurable diseases.
In a survey (*1) conducted among member doctors of E-Consult, a specialist consultation service for doctors provided by Medii, we encountered cases of IRD symptoms such as night blindness, tunnel vision, and nystagmus. 46.8% of doctors have experience in medical departments other than ophthalmology, and more than 90% of doctors with experience in IRD answered that they would like to consult an expert specialist, and that they would like to consult an expert specialist when they have clinical questions regarding IRD. It has become clear that many doctors have this problem.
To solve this problem, we formed an IRD specialist team on E-Consult with the cooperation of expert specialists with extensive experience in IRD treatment, and achieved collaboration among doctors in IRD treatment.
*1
A questionnaire survey was conducted targeting E-Consult member doctors (Number of valid respondents: 476 people, survey method: voluntary response via the internet, survey period: 2023/9/13~9/18)
* Initiative details *
As a specific initiative, Medii has launched a disease awareness site for doctors regarding IRD. Through this site, we have created an environment where patients can educate their doctors about the disease, and also use “E-Consult” to consult with IRD’s team of expert specialists for free via group chat regarding any questions they may have regarding actual medical treatment. By resolving the questions and concerns that attending physicians have, such as diagnosis, patient referral criteria, pros and cons of testing, and the burden and concerns on patients regarding genetic testing, we will help improve the diagnosis rate and optimize treatment for IRD.
* “Inherited Retinal Dystrophy” awareness site: * *
https://medii.jp/IRDconsultant*
Additionally, we will be holding an online seminar for doctors on the latest treatments for IRD on May 16th (Thursday), with a lecture by a doctor from a genetic testing facility.
Theme: Advances in genetic testing and gene therapy for inherited retinal dystrophy (IRD)
Lecturer: Kobe City Kobe Eye Center Hospital Research Center Dr. Akiko Maeda Date and time: May 16, 2024 (Thursday) 19:30-20:30
Venue: Online (Zoom)
Participation fee: Free
* Seminar details/application: * * https://medii.jp/seminar/20240516*
*About E-Consult*
E-Consult is a completely free online matching consultation service that allows attending physicians who are concerned about a patient’s diagnosis or treatment plan to discuss their case with a specialist who is not nearby via chat.
With the cooperation of more than 1,200 expert specialists, we provide consultation in all specialized fields and cover diseases that account for 99% of the number of patients with intractable diseases designated by the Ministry of Health, Labor and Welfare. You will be matched with the most suitable expert specialist depending on the consultation content, and the doctor will be able to consult anonymously via chat. In addition to one-on-one consultation, you can also consult with a group of experts in multiple fields (patented).
Details: https://medii.jp/e-consult
*About Medii*
Medii’s mission is to provide medical care that leaves no one behind. We have created a system that allows all doctors to easily access expert specialists with advanced knowledge in each field.
Representative Yamada is an active rheumatology specialist and also a patient with an immunologically intractable disease.The company name “Medii”, which means essence in Latin, symbolizes the problematic medical structure from the two-way perspective of doctors and patients. This reflects our desire to fundamentally change the system. In particular, we are aiming for early diagnosis and treatment optimization for rare and intractable diseases, which are major challenges for which specialized knowledge is tacit knowledge.
Company name: Medii Co., Ltd.
Address: THE GATE Shinjuku Gyoen 2F, 1-24-12 Shinjuku, Shinjuku-ku, Tokyo Established: February 20, 2020
Capital: 325 million yen
Representative: Representative Director and Doctor Hiroki Yamada URL: https://medii.jp
*E-Consult is a registered trademark of Medii Co., Ltd.
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000059.000060898.html
*Download press release materials*
https://prtimes.jp/im/action.php?run=html&page=releaseimage&company_id=60898&release_id=59
Unsubscribe HTML email
Copyright © PR TIMES Corporation All Rights Reserved.